---
title: "Trends in Breast, Cervical, and Colorectal Cancer Screening Utilization, 2010–2019 (Commercially I"
id: "medrxiv-8-trends-in-the-utilization-of-breast-cervical-and-colorectal-cancer-screening"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-8-trends-in-the-utilization-of-breast-cervical-and-colorectal-cancer-screening"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.09.26360037v1?rss=1"
published_at: "2026-08-11T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Trends in Breast, Cervical, and Colorectal Cancer Screening Utilization, 2010–2019 (Commercially I
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-8-trends-in-the-utilization-of-breast-cervical-and-colorectal-cancer-screening
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.09.26360037v1?rss=1)
- **Published At:** 2026-08-11T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Analysis of MarketScan commercial claims (2010–2019) covering ~141.2 million privately insured enrollees assessed annual utilization of **breast**, **cervical**, and **colorectal cancer screening** by age, modality, and region. - Annual screening rates were defined as the proportion of eligible enrollees receiving a given test within each calendar year; these reflect **annual utilization**, not guideline-concordant up-to-date screening. - Temporal trends were evaluated using two-sided Poisson regression; 2019 urban–rural differences were assessed with multivariate generalized estimating equations. - Cervical screening: cervical cytology alone among women aged 30–64 fell from 28.2% (2010) to 8.8% (2019); co-testing rose from 11.4% to 20.3% over the same period. - Breast screening: screening mammography among women aged 50–64 remained essentially unchanged (45.7% in 2010 vs 45.8% in 2019). - Colorectal screening: annual utilization among enrollees aged <64 decreased from 7.7% (2010) to 6.5% (2019), with a larger decline in adults aged 45–49 years. - Across all three cancers, screening utilization was consistently higher in urban versus rural residents in 2019; incidence rate ratios ranged roughly 1.02–1.05. - Overall conclusion: utilization of these preventive screening tests did not improve from 2010 to 2019 among commercially insured adults, and persistent urban–rural disparities point to gaps in preventive care delivery. - Data access limited by MarketScan licensing; ethical oversight: Johns Hopkins IRB waived approval; authors reported no competing interests.
## Clinical Analysis & Structured Key Points
Trends in the Utilization of Breast, Cervical, and Colorectal Cancer Screening from 2010 to 2019 Among a Commercially Insured Population Using the MarketScan Commercial Claims Database | medRxiv Skip to main content Trends in the Utilization of Breast, Cervical, and Colorectal Cancer Screening from 2010 to 2019 Among a Commercially Insured Population Using the MarketScan Commercial Claims Database View ORCID Profile JingJing Sun , View ORCID Profile Ricky Wat , View ORCID Profile K. Davina Frick , View ORCID Profile Xiangrong Kong , View ORCID Profile Hailun Liang , View ORCID Profile Clifton Chow , View ORCID Profile Leiyu Shi doi: https://doi.org/10.64898/2026.08.09.26360037 JingJing Sun 1 Johns Hopkins Bloomberg School of Public Health; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for JingJing Sun For correspondence: jsun53{at}jhu.edu Ricky Wat 2 MCPHS University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ricky Wat K. Davina Frick 1 Johns Hopkins Bloomberg School of Public Health; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for K. Davina Frick Xiangrong Kong 1 Johns Hopkins Bloomberg School of Public Health; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Xiangrong Kong Hailun Liang 3 Renmin University of China; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Hailun Liang Clifton Chow 4 Harvard Medical School Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Clifton Chow Leiyu Shi 1 Johns Hopkins Bloomberg School of Public Health; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Leiyu Shi Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Introduction: Breast, cervical, and colorectal cancer screening guidelines changed substantially between 2010 and 2019. We examined trends in the annual utilization of these screenings among commercially insured enrollees in the United States from 2010 to 2019 by age group, geographic region, and screening modality. Methods: We conducted a retrospective, serial cross-sectional analysis of the MarketScan Commercial Claims Database from 2010 through 2019, comprising approximately 141.2 million privately insured enrollees. Annual screening rates, defined as the proportion of eligible enrollees receiving a given test within each calendar year, were estimated for cervical, breast, and colorectal cancer using procedure codes, stratified by age group, screening modality, and geographic residence. These reflect annual utilization rather than up-to-date (guideline-concordant) screening. Temporal trends were evaluated using two-sided Poisson regression, and urban-rural disparities in 2019 were assessed using multivariate generalized estimating equations. Results: Cancer screening utilization remained stagnant or declined across all three cancer types over the study period. Among women aged 30-64 years, cervical cytology alone declined substantially from 28.2% in 2010 to 8.8% in 2019, while co-testing increased from 11.4% to 20.3%. Screening mammography among women aged 50-64 showed minimal change, remaining stable at 45.7% in 2010 and 45.8% in 2019. Colorectal cancer screening across enrollees aged <64 decreased modestly from 7.7% in 2010 to 6.5% in 2019, with a more pronounced decline among adults aged 45-49 years. Across all three cancer types, screening utilization was higher among urban residents than rural residents, with incidence rate ratios ranging from 1.02 to 1.05 in 2019. Conclusions: Utilization of cervical, breast, and colorectal cancer screening among commercially insured adults did not improve between 2010 and 2019. Persistent urban-rural disparities highlight ongoing gaps in preventive care delivery. Targeted interventions may help improve screening utilization, particularly in rural and underserved populations. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Institutional Review Board of Johns Hopkins Bloomberg School of Public Health waived ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data underlying the results presented in the study are available from the Merative MarketScan Commercial Claims and Encounters Database. Data cannot be shared publicly because of data use agreement restrictions and licensing limitations. MarketScan data are available for licensing from Merative (formerly IBM Watson Health) at https://www.merative.com https://www.merative.com Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted August 11, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Trends in the Utilization of Breast, Cervical, and Colorectal Cancer Screening from 2010 to 2019 Among a Commercially Insured Population Using the MarketScan Commercial Claims Database Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Trends in the Utilization of Breast, Cervical, and Colorectal Cancer Screening from 2010 to 2019 Among a Commercially Insured Population Using the MarketScan Commercial Claims Database JingJing Sun , Ricky Wat , K. Davina Frick , Xiangrong Kong , Hailun Liang , Clifton Chow , Leiyu Shi medRxiv 2026.08.09.26360037; doi: https://doi.org/10.64898/2026.08.09.26360037 Share This Article: Copy Citation Tools Trends in the Utilization of Breast, Cervical, and Colorectal Cancer Screening from 2010 to 2019 Among a Commercially Insured Population Using the MarketScan Commercial Claims Database JingJing Sun , Ricky Wat , K. Davina Frick , Xiangrong Kong , Hailun Liang , Clifton Chow , Leiyu Shi medRxiv 2026.08.09.26360037; doi: https://doi.org/10.64898/2026.08.09.26360037 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (601) Allergy and Immunology (891) Anesthesia (322) Cardiovascular Medicine (4708) Dentistry and Oral Medicine (467) Dermatology (403) Emergency Medicine (632) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1599) Epidemiology (15697) Forensic Medicine (32) Gastroenterology (1185) Genetic and Genomic Medicine (6904) Geriatric Medicine (722) Health Economics (1039) Health Informatics (4891) Health Policy (1415) Health Systems and Quality Improvement (1712) Hematology (570) HIV/AIDS (1313) Infectious Diseases (except HIV/AIDS) (16175) Intensive Care and Critical Care Medicine (1151) Medical Education (653) Medical Ethics (150) Nephrology (710) Neurology (7077) Nursing (358) Nutrition (1062) Obstetrics and Gynecology (1212) Occupational and Environmental Health (989) Oncology (3529) Ophthalmology (1017) Orthopedics (383) Otolaryngology (436) Pain Medicine (460) Palliative Medicine (136) Pathology (696) Pediatrics (1757) Pharmacology and Therapeutics (726) Primary Care Research (753) Psychiatry and Clinical Psychology (5756) Public and Global Health (9584) Radiology and Imaging (2342) Rehabilitation Medicine and Physical Therapy (1412) Respiratory Medicine (1231) Rheumatology (629) Sexual and Reproductive Health (758) Sports Medicine (569) Surgery (753) Toxicology (105) Transplantation (300) Urology (280)
## Related Clinical Research

- [KaroLiver cohort: population-based dataset of curative liver-directed treatment for colorectal liv](https://medichelpline.com/clinical-feed/medrxiv-9-cohort-profile-karoliver-a-population-based-cohort-of-patients-receiving.md)
- [Mendelian Randomisation Study Linking the Oral Microbiome to Oral, Oropharyngeal, and Tongue Cance](https://medichelpline.com/clinical-feed/pubmed-42583788.md) (DOI: 10.3290/j.ohpd.c_2778)
- [Polygenic risk score predicts colorectal cancer across six ancestries and may inform screening](https://medichelpline.com/clinical-feed/medrxiv-12-genetic-prediction-of-colorectal-cancer-risk-in-six-major-ancestries-provides.md)
- [Arginine supplements and immune recognition: mouse study links arginine to improved cancer and vir](https://medichelpline.com/clinical-feed/medical-news-today-0-could-arginine-supplements-help-boost-immune-responses-to-cancer-viruses.md)
- [Vitamin D3 dosing in metastatic colorectal cancer: SOLARIS phase 3 trial findings](https://medichelpline.com/clinical-feed/medical-news-today-0-vitamin-d-may-aid-late-stage-colorectal-cancer-treatment-but-which-dosage-is.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.